IP Library Granted Patent US 10,112,980
Granted Patent B2
US 10,112,980 · App. 15/598,685 · Granted Oct 30, 2018

Mutated immunoglobulin-binding polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,112,980
App. No.
15/598,685
Granted
Oct 30, 2018
Kind
B2
Abstract

The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.

Claims (25)

1. A separation matrix, comprising a plurality of polypeptides or multimers of the polypeptides coupled to a solid support, wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 6-10, 12, 13, or a combination thereof.

2. The separation matrix of claim 1 , wherein the polypeptides or multimers thereof have been coupled to the solid support via thioether bonds.

3. The separation matrix of claim 1 , wherein the solid support is a polysaccharide.

4. A method of isolating an immunoglobulin using the separation matrix of claim 1 , the method comprising the steps of: a) contacting a liquid sample comprising an immunoglobulin with the separation matrix of claim 1 , b) washing said separation matrix with a washing liquid, c) eluting the immunoglobulin from the separation matrix with an elution liquid, and d) cleaning the separation matrix with a cleaning liquid.

5. The method of claim 4 , wherein the cleaning liquid is alkaline having a pH of 13-14.

6. The method of claim 4 , wherein the cleaning liquid comprises 0.1-1.0 M NaOH or KOH.

7. The method of claim 4 , wherein steps a)-d) are repeated at least 10 times.

8. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 6.

9. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 7.

10. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

11. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 9.

12. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 10.

13. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 12.

14. The separation matrix of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 13.

15. The separation matrix of claim 1 , wherein the polypeptide is the amino acid multimer with each monomer of the multimer comprising a sequence of any one of SEQ ID NOS: 6-10, 12, or 13.

16. The separation matrix of claim 1 , wherein the polypeptide is the amino acid multimer with each monomer comprising a sequence of SEQ ID NO: 6.

17. The separation matrix of claim 1 , wherein polypeptide is the amino acid multimer with each monomer comprising a sequence of SEQ ID NO: 7.

18. The separation matrix of claim 1 , wherein the polypeptide is the amino acid multimer with each monomer comprising a sequence of SEQ ID NO: 8.

19. The separation matrix of claim 1 , wherein the polypeptide is the amino acid multimer with each monomer comprising a sequence of SEQ ID NO: 9.

20. The separation matrix of claim 1 , wherein the polypeptide is the amino acid multimer with each monomer comprising a sequence of SEQ ID NO: 10.

21. The separation matrix of claim 1 , wherein the polypeptide is a multimer with each monomer comprising a sequence of SEQ ID NO: 12.

22. The separation matrix of claim 1 , wherein the polypeptide is a multimer with each monomer comprising a sequence of SEQ ID NO: 13.

23. The separation matrix of claim 1 , wherein the multimer comprises a plurality of the polypeptide units linked by elements comprising up to 15 amino acids.

24. The separation matrix of claim 1 , wherein the multimer is a dimer, trimer, tetramer, pentamer or hexamer.

25. The separation matrix of claim 1 , further comprising at the C-terminal or N-terminal of the polypeptide or multimer of the polypeptide one or more coupling element to couple the polypeptide to the support, wherein the coupling element is selected from the group consisting of a cysteine residue, a plurality of lysine residues and a plurality of histidine residues.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 043619/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2017
From: ANDER, MATS; BAUREN, GORAN; BJORKMAN, TOMAS; RODRIGO, GUSTAV
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 042427/0121 →